DMD and Duchenne muscular dystrophy: Treatment of juvenile ΔEx44 mice, which would better mirror ongoing clinical trials treating DMD patients in middle childhood (6–11 years), could also restore dystrophin levels to >25% of WT levels in TA muscle and >35% of WT levels in cardiac muscle and decrease pathological features, such as the percentage of centrally nucleated fibers.